BioSig subsidiary raises $1.71M in private placement; parent retains 87.5% ownership

Streamex Corp.

BioSig AI Sciences sold 1,710,000 shares to accredited investors at $1.00/share, raising $1.71M.
Before the placement BioSig owned 100% of BioSig AI; after closing it holds about 87.5%.
Laidlaw & Co (UK) Ltd received a warrant to buy 90,000 shares at $1.00, exercisable for 5 years.
Shares and Laidlaw warrant issued under Section 4(a)(2) and Regulation D exemption.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Streamex Corp. entered into Securities Purchase Agreement with certain accredited investors valued at $1,710,000 (effective 2023-06-30).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: $1,710,000
Effective: 2023-06-30

Exact text from the filing

On June 30, 2023, BioSig AI Sciences, Inc., f/k/a NeuroClear Technologies Inc. (“BioSig AI”), a subsidiary of BioSig Technologies, Inc. (“BioSig”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which BioSig AI agreed to sell an aggregate of 1,710,000 shares (the “Shares”) of BioSig AI’s common stock, par value $0.001 per share (the “Common Stock”) for an aggregate purchase price of $1,710,000 (the “BioSig AI Private Placement”).

View on SEC.gov

277 material agreements filed in the last 30 days. Browse all material agreements →

Streamex Corp. filing history →

Source: SEC EDGAR

accession 0001185185-23-000682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.